NEU.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 03:48):

Stats
Dzisiejszy wolumen	44 873.00
Średni wolumen	507 662
Kapitalizacja rynkowa	2.42B
EPS	$0 ( 2024-02-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	15.83
ATR14	$0.0420 (0.22%)

Wolumen Korelacja

Długi: -0.26 (neutral)

Krótki: -0.02 (neutral)

Signal:(60.401) Neutral

Neuren Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neuren Pharmaceuticals Korelacja - Waluta/Towar

0.34
( neutral )

0.39
( neutral )

0.00
( neutral )

0.09
( neutral )

-0.06
( neutral )

0.22
( neutral )

Neuren Pharmaceuticals Finanse

Annual	2023
Przychody:	$231.93M
Zysk brutto:	$205.17M (88.47 %)
EPS:	$1.240

FY	2023
Przychody:	$231.93M
Zysk brutto:	$205.17M (88.47 %)
EPS:	$1.240

FY	2022
Przychody:	$14.55M
Zysk brutto:	$14.54M (99.93 %)
EPS:	$0.00150

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0728

Financial Reports:

No articles found.

Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.